Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-542-3p mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-542-3p mimic is a chemically synthesized, double-stranded RNA oligonucleotide designed to replicate the biological activity of the endogenous microRNA miR-542-3p. As a microRNA mimic, it functions by binding to the 3′-untranslated regions (UTRs) of specific target mRNAs, leading to translational inhibition or mRNA degradation. In preclinical research, miR-542-3p has been identified as a tumor suppressor in various cancers, including glioma, osteosarcoma, and HER2-overexpressing breast cancer. Key validated targets include Survivin (BIRC5), Hexokinase 2 (HK2), VANGL2, and Integrin-linked kinase (ILK). By downregulating these targets, the mimic can inhibit cellular proliferation, migration, and glycolytic activity. It is primarily utilized as a research tool and is available through various laboratory reagent suppliers.
- Other names
- microRNA-542-3p mimicmicroRNA542-3p mimicmicroRNA 542-3p mimichsa-miR-542-3p mimichsa-miR542-3p mimichsa-miR 542-3p mimic
02
Targets
PTEN (Phosphatase and tensin homolog deleted on chromosome ten)BIRC5 (Survivin)Phosphofructokinase, muscle (PFKM) mRNAHK2 (Hexokinase Type II)ERBB3 (Erb-b2 receptor tyrosine kinase 3)Integrin-linked kinase mRNA (ILK mRNA)SMAD2 (Mothers against decapentaplegic homolog 2)
Beyond the preview
Go deeper on miR-542-3p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-542-3p mimic.